New analysis puts a multi-billion-dollar value on progress as Japan opens new scientific pathways for ALS discovery.
According to new research from the UK’s Office of Health Economics (OHE), the rewards of successfully treating amyotrophic lateral sclerosis (ALS) could be counted not only in lives improved but in billions of dollars saved and earned. The analysis, commissioned by Challenge Works, estimates that effective treatments for ALS could be worth around $26–40 billion in the US over a decade, with potential global value exceeding $143 billion if the disease were eradicated [1]. For a condition so rare yet so ruinous, the numbers reframe ALS as both a moral and economic imperative – a health challenge where scientific innovation and societal return are tightly entwined.
At the same time, Japan’s Toray Industries and Aichi Medical University have launched an open innovation framework designed to speed ALS drug discovery. The initiative draws on a jointly developed drug efficacy evaluation technology built around patient-derived induced pluripotent stem cells (iPSCs), allowing researchers to model diverse pathological states of ALS and predict the impact of new compounds more precisely. By opening the platform to collaboration with pharmaceutical companies, the partners aim to improve success rates in a disease where progress has too often been slow and sporadic.
Longevity.Technology: ALS sits at the intersection of urgency and opportunity – a disease so devastating it demands innovation, yet so complex it has long deterred investment. The new OHE analysis gives this challenge a harder edge of economic realism, putting numbers to what longevity science has argued for years: that prevention and recovery are not only moral imperatives, but commercial ones. Quantifying the value of restored function – and the cost of its absence – shifts the frame from charity to strategy.
Meanwhile, Japan’s Toray–Aichi initiative illustrates how that logic translates to the bench; by opening its iPSC-based evaluation platform to wider collaboration, it turns discovery into a shared enterprise rather than a proprietary gamble. Taken together, these developments hint that the business of neurodegeneration is evolving – from speculative moonshot to measurable return, from promise to proof – and that longevity’s next frontier may be the art of pricing resilience. For investors and policymakers, it’s a reminder that aging science yields dividends in both human and financial capital when the right incentives meet the right infrastructure.
Counting the cost of delay
ALS, the most common form of motor neurone disease, remains incurable. It robs individuals of movement and speech while leaving cognition largely intact, and life expectancy after diagnosis is typically two to five years. Despite multiple clinical trials, most candidate drugs have failed, often because the disease’s heterogeneity makes results hard to predict. The OHE study quantifies the toll in human and economic terms: in the UK, the disease costs the National Health Service around £133 million ($175 million) annually – triple that when lost productivity and informal care are included.
Dr Amanda Cole, Director at OHE, said: “The burden of ALS is particularly stark when expressed in terms of quality-adjusted life years (QALYs) lost. In the UK, an individual diagnosed with ALS may lose (on average) 12.6 QALYs over their lifetime. Furthermore, ALS patients require intensive care, placing huge strain on healthcare systems, as well as families and support networks. The value of an effective treatment would be significant, and lifechanging for those living with the disease.”
Economic logic meets innovation
For investors, those numbers suggest that the case for ALS innovation is no longer purely humanitarian. As Dr Vishal Gulati, Founder and Managing Partner of Recode Ventures and a judge for the Longitude Prize on ALS, put it: “ALS offers biopharmaceutical companies strategic convergence where urgent unmet need meets compelling commercial opportunity. Investing here makes strategic sense: rapid disease progression enables shorter, more cost-effective trials; approved treatments have seen fast uptake; platform trials allow multiple drugs to be tested efficiently; and orphan status accelerates regulatory approval. Crucially, ALS also acts as a proof-of-concept for technologies that could be applied to other neurodegenerative diseases, unlocking further opportunities. Breakthroughs are urgently needed, and OHE’s research makes a strong case for investing in this area.”
This blend of moral urgency and economic rationale is already shaping global initiatives. In Japan, Toray and Aichi Medical University’s new framework exemplifies how collaborative infrastructure can lower the barrier for drug development. Their technology uses iPSCs derived from ALS patients to reproduce the condition in culture, allowing potential therapies to be tested with greater precision and consistency. The aim is to move promising compounds through preclinical evaluation more swiftly – and with fewer false starts – by capturing the disease’s molecular diversity in vitro.
Building on work supported by Japan’s Agency for Medical Research and Development (AMED), the partners have created an integrated evaluation platform that combines customized equipment and high-precision data workflows to assess candidate drugs. The system can replicate the varied pathological states seen across ALS patients, making it possible to predict efficacy more accurately than conventional models. Developed under Japan’s GAPFREE initiative, which links government, academia and private enterprise, the framework invites pharmaceutical companies to test their own compounds within this shared system – a rare example of open innovation in a traditionally insular R&D environment. Toray and Aichi hope this approach will not only accelerate ALS drug discovery but also improve reproducibility across neurodegenerative research more broadly.
Incentives for acceleration
The OHE analysis was commissioned alongside the launch of the £7.5 million Longitude Prize on ALS, a global challenge prize encouraging AI-based drug discovery for the disease. The prize, run by Challenge Works and funded by the Motor Neurone Disease Association and partners, seeks to attract new minds to an area historically seen as high risk and low reward.
Tris Dyson, Managing Director at Challenge Works, said: “For too long, ALS has been an area of high risk and low investment, but things are changing. Advances in AI, combined with better understanding of the disease and higher volumes of patient data, mean that we find ourselves at a turning point for uncovering potential new treatment pathways. OHE’s research quantifies the significant value this would bring to individuals and societies, and we hope the Longitude Prize on ALS will mark a step towards discovering new treatments, and edge us ever closer to a cure.”
By positioning innovation as a value proposition as well as a moral one, the OHE report and its associated initiatives are reframing ALS as an exemplar for how to accelerate neurodegenerative disease research. The intersection of better economics, stronger models and smarter incentives may be precisely what the field needs to convert urgency into progress.
The measure of momentum
ALS remains a hard problem, but it is no longer a neglected one. From Japan’s open-lab model to the UK’s economic mapping of disease value, the forces driving its research are broadening. For longevity science, that’s good news; ALS sits close to the heart of neurodegeneration, and every insight gleaned has echoes across the wider terrain of aging biology. The challenge now is to maintain momentum – ensuring that the economics of healthspan translate into action before time runs out for those living with this most unforgiving of diseases.
[1] https://www.ohe.org/publications/the-commercial-case-for-investing-in-als
